123 related articles for article (PubMed ID: 16175083)
1. Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein.
Armes JE; Lourie R; de Silva M; Stamaratis G; Boyd A; Kumar B; Price G; Hyde S; Allen D; Grant P; Venter DJ
Int J Gynecol Pathol; 2005 Oct; 24(4):363-8. PubMed ID: 16175083
[TBL] [Abstract][Full Text] [Related]
2. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
3. Analysis of p53, p16(INK4a), pRb and Cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas.
Bilyk OO; Pande NT; Buchynska LG
Exp Oncol; 2011 Sep; 33(3):150-6. PubMed ID: 21956468
[TBL] [Abstract][Full Text] [Related]
4. Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma.
Milea A; George SH; Matevski D; Jiang H; Madunic M; Berman HK; Gauthier ML; Gallie B; Shaw PA
Mod Pathol; 2014 Jul; 27(7):991-1001. PubMed ID: 24336157
[TBL] [Abstract][Full Text] [Related]
5. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
[TBL] [Abstract][Full Text] [Related]
6. Expression of p16 in serous ovarian neoplasms.
Nazlioglu HO; Ercan I; Bilgin T; Ozuysal S
Eur J Gynaecol Oncol; 2010; 31(3):312-4. PubMed ID: 21077476
[TBL] [Abstract][Full Text] [Related]
7. P16(INK4a) protein expression in endocervical, endometrial and metastatic adenocarcinomas of extra-uterine origin: diagnostic and clinical considerations.
Caponio MA; Addati T; Popescu O; Petroni S; Rubini V; Centrone M; Trojano G; Simone G
Cancer Biomark; 2014; 14(2-3):169-75. PubMed ID: 24878818
[TBL] [Abstract][Full Text] [Related]
8. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms.
Giordano G; Azzoni C; D'Adda T; Rocco A; Gnetti L; Froio E; Merisio C; Melpignano M
Pathol Res Pract; 2008; 204(3):163-74. PubMed ID: 18180113
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic implications of p16 expression in serous papillary endometrial cancer.
Netzer IM; Kerner H; Litwin L; Lowenstein L; Amit A
Int J Gynecol Cancer; 2011 Nov; 21(8):1441-5. PubMed ID: 22027748
[TBL] [Abstract][Full Text] [Related]
10. PAX 2: a novel Müllerian marker for serous papillary carcinomas to differentiate from micropapillary breast carcinoma.
Chivukula M; Dabbs DJ; O'Connor S; Bhargava R
Int J Gynecol Pathol; 2009 Nov; 28(6):570-8. PubMed ID: 19851209
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of Rb1, P16 and ER as diagnostic, prognostic and potential targets for therapeutic agents in ovarian epithelial tumors: an immunohistochemical study of 130 ovarian carcinomas.
Ferguson DC; Long DJ; Smith MC; Craig-Owens LD; Means J; Fadare O; Desouki MM
J Ovarian Res; 2015 Jun; 8():34. PubMed ID: 26043844
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
[TBL] [Abstract][Full Text] [Related]
13. Expression of p53, p21WAF1/CIP1, p16INK4A and Ki-67 proteins in serous ovarian tumors.
Buchynska LG; Nesina IP; Yurchenko NP; Bilyk OO; Grinkevych VN; Svintitsky VS
Exp Oncol; 2007 Mar; 29(1):49-53. PubMed ID: 17431389
[TBL] [Abstract][Full Text] [Related]
14. Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma.
Phillips V; Kelly P; McCluggage WG
Int J Gynecol Pathol; 2009 Mar; 28(2):179-86. PubMed ID: 19188815
[TBL] [Abstract][Full Text] [Related]
15. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
16. beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma.
Lee CM; Shvartsman H; Deavers MT; Wang SC; Xia W; Schmandt R; Bodurka DC; Atkinson EN; Malpica A; Gershenson DM; Hung MC; Lu KH
Gynecol Oncol; 2003 Mar; 88(3):363-8. PubMed ID: 12648588
[TBL] [Abstract][Full Text] [Related]
17. Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas.
Halperin R; Zehavi S; Dar P; Habler L; Hadas E; Bukovsky I; Schneider D
Eur J Gynaecol Oncol; 2001; 22(4):292-6. PubMed ID: 11695812
[TBL] [Abstract][Full Text] [Related]
18. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour.
O'Neill CJ; McBride HA; Connolly LE; Deavers MT; Malpica A; McCluggage WG
Histopathology; 2007 May; 50(6):773-9. PubMed ID: 17493241
[TBL] [Abstract][Full Text] [Related]
19. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotypic Analysis in Early Müllerian Serous Carcinogenesis.
Nafisi H; Ghorab Z; Ismill N; Dubé V; Plotkin A; Han G; Cesari M; Lu FI; Saad R; Khalifa M; Nofech-Mozes S
Int J Gynecol Pathol; 2015 Sep; 34(5):424-36. PubMed ID: 26107560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
